Condition
Liver, Cancer of, Primary Resectable
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 3 (1)
Trial Status
Unknown1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT06214533Not ApplicableUnknown
Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery
NCT05701436Phase 3RecruitingPrimary
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial
Showing all 2 trials